nodes	percent_of_prediction	percent_of_DWPC	metapath
Gliclazide—KCNJ11—epilepsy syndrome	0.167	0.424	CbGaD
Gliclazide—VEGFA—epilepsy syndrome	0.13	0.329	CbGaD
Gliclazide—CYP2C19—epilepsy syndrome	0.0628	0.159	CbGaD
Gliclazide—ALB—epilepsy syndrome	0.0349	0.0883	CbGaD
Gliclazide—ALB—Oxcarbazepine—epilepsy syndrome	0.0264	0.0734	CbGbCtD
Gliclazide—ALB—Fosphenytoin—epilepsy syndrome	0.023	0.0642	CbGbCtD
Gliclazide—ALB—Clonazepam—epilepsy syndrome	0.0208	0.058	CbGbCtD
Gliclazide—CYP2C19—Oxcarbazepine—epilepsy syndrome	0.0171	0.0476	CbGbCtD
Gliclazide—ALB—Rufinamide—epilepsy syndrome	0.017	0.0473	CbGbCtD
Gliclazide—CYP2C19—Felbamate—epilepsy syndrome	0.0159	0.0443	CbGbCtD
Gliclazide—CYP2C19—Trimethadione—epilepsy syndrome	0.0159	0.0443	CbGbCtD
Gliclazide—CYP2C19—Fosphenytoin—epilepsy syndrome	0.0149	0.0416	CbGbCtD
Gliclazide—ALB—Phenytoin—epilepsy syndrome	0.0148	0.0414	CbGbCtD
Gliclazide—ALB—Propofol—epilepsy syndrome	0.0138	0.0386	CbGbCtD
Gliclazide—CYP2C9—Trimethadione—epilepsy syndrome	0.0132	0.0368	CbGbCtD
Gliclazide—CYP2C19—Clobazam—epilepsy syndrome	0.013	0.0361	CbGbCtD
Gliclazide—ALB—Diazepam—epilepsy syndrome	0.0125	0.0349	CbGbCtD
Gliclazide—CYP2C9—Fosphenytoin—epilepsy syndrome	0.0124	0.0346	CbGbCtD
Gliclazide—CYP2C19—Carbamazepine—epilepsy syndrome	0.0107	0.0299	CbGbCtD
Gliclazide—CYP2C19—Primidone—epilepsy syndrome	0.01	0.0279	CbGbCtD
Gliclazide—CYP2C19—Phenytoin—epilepsy syndrome	0.00963	0.0268	CbGbCtD
Gliclazide—CYP2C19—Propofol—epilepsy syndrome	0.00898	0.025	CbGbCtD
Gliclazide—CYP2C9—Carbamazepine—epilepsy syndrome	0.00892	0.0249	CbGbCtD
Gliclazide—CYP2C19—Phenobarbital—epilepsy syndrome	0.00858	0.0239	CbGbCtD
Gliclazide—CYP2C9—Primidone—epilepsy syndrome	0.00833	0.0232	CbGbCtD
Gliclazide—CYP2C19—Diazepam—epilepsy syndrome	0.00813	0.0227	CbGbCtD
Gliclazide—CYP2C9—Phenytoin—epilepsy syndrome	0.008	0.0223	CbGbCtD
Gliclazide—CYP2C19—Zonisamide—epilepsy syndrome	0.00794	0.0221	CbGbCtD
Gliclazide—CYP2C9—Propofol—epilepsy syndrome	0.00746	0.0208	CbGbCtD
Gliclazide—CYP2C9—Phenobarbital—epilepsy syndrome	0.00713	0.0199	CbGbCtD
Gliclazide—CYP2C9—Diazepam—epilepsy syndrome	0.00676	0.0188	CbGbCtD
Gliclazide—CYP2C19—Valproic Acid—epilepsy syndrome	0.00641	0.0179	CbGbCtD
Gliclazide—CYP2C19—Topiramate—epilepsy syndrome	0.00579	0.0161	CbGbCtD
Gliclazide—CYP2C9—Valproic Acid—epilepsy syndrome	0.00533	0.0148	CbGbCtD
Gliclazide—VEGFA—telencephalon—epilepsy syndrome	0.000476	0.0969	CbGeAlD
Gliclazide—Tolazamide—KCNJ11—epilepsy syndrome	0.000459	0.137	CrCbGaD
Gliclazide—Glisoxepide—KCNJ11—epilepsy syndrome	0.000415	0.124	CrCbGaD
Gliclazide—Glimepiride—KCNJ11—epilepsy syndrome	0.000409	0.122	CrCbGaD
Gliclazide—Glipizide—KCNJ11—epilepsy syndrome	0.000355	0.106	CrCbGaD
Gliclazide—ABCC8—brainstem—epilepsy syndrome	0.000354	0.0719	CbGeAlD
Gliclazide—ABCC8—forebrain—epilepsy syndrome	0.000341	0.0694	CbGeAlD
Gliclazide—VEGFA—spinal cord—epilepsy syndrome	0.000334	0.0679	CbGeAlD
Gliclazide—ABCC8—telencephalon—epilepsy syndrome	0.000314	0.0638	CbGeAlD
Gliclazide—Tolbutamide—SLCO1A2—epilepsy syndrome	0.000283	0.0843	CrCbGaD
Gliclazide—VEGFA—cerebellum—epilepsy syndrome	0.000265	0.0538	CbGeAlD
Gliclazide—Chlorpropamide—KCNJ11—epilepsy syndrome	0.000257	0.0766	CrCbGaD
Gliclazide—Tolbutamide—KCNJ11—epilepsy syndrome	0.00025	0.0746	CrCbGaD
Gliclazide—ABCC8—medulla oblongata—epilepsy syndrome	0.000247	0.0502	CbGeAlD
Gliclazide—ABCC8—midbrain—epilepsy syndrome	0.000225	0.0458	CbGeAlD
Gliclazide—ABCC8—spinal cord—epilepsy syndrome	0.00022	0.0447	CbGeAlD
Gliclazide—VEGFA—brain—epilepsy syndrome	0.000215	0.0437	CbGeAlD
Gliclazide—KCNJ11—head—epilepsy syndrome	0.000212	0.0432	CbGeAlD
Gliclazide—KCNJ11—nervous system—epilepsy syndrome	0.000201	0.0409	CbGeAlD
Gliclazide—Glyburide—SLCO1A2—epilepsy syndrome	0.000196	0.0585	CrCbGaD
Gliclazide—ABCC8—head—epilepsy syndrome	0.000195	0.0398	CbGeAlD
Gliclazide—KCNJ11—central nervous system—epilepsy syndrome	0.000194	0.0394	CbGeAlD
Gliclazide—KCNJ11—cerebellum—epilepsy syndrome	0.000189	0.0385	CbGeAlD
Gliclazide—ABCC8—nervous system—epilepsy syndrome	0.000185	0.0377	CbGeAlD
Gliclazide—ABCC8—central nervous system—epilepsy syndrome	0.000178	0.0363	CbGeAlD
Gliclazide—ABCC8—cerebellum—epilepsy syndrome	0.000174	0.0355	CbGeAlD
Gliclazide—Glyburide—KCNJ11—epilepsy syndrome	0.000173	0.0517	CrCbGaD
Gliclazide—KCNJ11—brain—epilepsy syndrome	0.000154	0.0313	CbGeAlD
Gliclazide—ABCC8—brain—epilepsy syndrome	0.000142	0.0288	CbGeAlD
Gliclazide—ALB—brain—epilepsy syndrome	0.000101	0.0206	CbGeAlD
Gliclazide—Chlorpropamide—CYP2C19—epilepsy syndrome	9.64e-05	0.0288	CrCbGaD
Gliclazide—Tolbutamide—CYP2C19—epilepsy syndrome	9.4e-05	0.028	CrCbGaD
Gliclazide—Glyburide—ABCC2—epilepsy syndrome	9.37e-05	0.028	CrCbGaD
Gliclazide—Glyburide—ABCG2—epilepsy syndrome	8.28e-05	0.0247	CrCbGaD
Gliclazide—Glyburide—CYP2C19—epilepsy syndrome	6.51e-05	0.0194	CrCbGaD
Gliclazide—Chlorpropamide—ABCB1—epilepsy syndrome	5.1e-05	0.0152	CrCbGaD
Gliclazide—Glyburide—ALB—epilepsy syndrome	3.61e-05	0.0108	CrCbGaD
Gliclazide—Glyburide—ABCB1—epilepsy syndrome	3.45e-05	0.0103	CrCbGaD
Gliclazide—Cough—Pregabalin—epilepsy syndrome	2.78e-05	0.000177	CcSEcCtD
Gliclazide—Pruritus—Phenytoin—epilepsy syndrome	2.77e-05	0.000177	CcSEcCtD
Gliclazide—Nausea—Levetiracetam—epilepsy syndrome	2.77e-05	0.000177	CcSEcCtD
Gliclazide—Rash—Vigabatrin—epilepsy syndrome	2.77e-05	0.000177	CcSEcCtD
Gliclazide—Dizziness—Felbamate—epilepsy syndrome	2.77e-05	0.000176	CcSEcCtD
Gliclazide—Dermatitis—Vigabatrin—epilepsy syndrome	2.77e-05	0.000176	CcSEcCtD
Gliclazide—Pruritus—Oxcarbazepine—epilepsy syndrome	2.76e-05	0.000176	CcSEcCtD
Gliclazide—Convulsion—Pregabalin—epilepsy syndrome	2.76e-05	0.000176	CcSEcCtD
Gliclazide—Hypersensitivity—Carbamazepine—epilepsy syndrome	2.76e-05	0.000176	CcSEcCtD
Gliclazide—Headache—Vigabatrin—epilepsy syndrome	2.75e-05	0.000175	CcSEcCtD
Gliclazide—Hypertension—Pregabalin—epilepsy syndrome	2.75e-05	0.000175	CcSEcCtD
Gliclazide—Vomiting—Diazepam—epilepsy syndrome	2.75e-05	0.000175	CcSEcCtD
Gliclazide—Tremor—Gabapentin—epilepsy syndrome	2.74e-05	0.000174	CcSEcCtD
Gliclazide—Rash—Diazepam—epilepsy syndrome	2.73e-05	0.000174	CcSEcCtD
Gliclazide—Dermatitis—Diazepam—epilepsy syndrome	2.72e-05	0.000174	CcSEcCtD
Gliclazide—Visual impairment—Topiramate—epilepsy syndrome	2.72e-05	0.000173	CcSEcCtD
Gliclazide—Chest pain—Pregabalin—epilepsy syndrome	2.71e-05	0.000173	CcSEcCtD
Gliclazide—Myalgia—Pregabalin—epilepsy syndrome	2.71e-05	0.000173	CcSEcCtD
Gliclazide—Arthralgia—Pregabalin—epilepsy syndrome	2.71e-05	0.000173	CcSEcCtD
Gliclazide—Ill-defined disorder—Gabapentin—epilepsy syndrome	2.71e-05	0.000173	CcSEcCtD
Gliclazide—Dizziness—Zonisamide—epilepsy syndrome	2.71e-05	0.000173	CcSEcCtD
Gliclazide—Headache—Diazepam—epilepsy syndrome	2.71e-05	0.000173	CcSEcCtD
Gliclazide—Anxiety—Pregabalin—epilepsy syndrome	2.7e-05	0.000172	CcSEcCtD
Gliclazide—Diarrhoea—Clonazepam—epilepsy syndrome	2.7e-05	0.000172	CcSEcCtD
Gliclazide—Anaemia—Gabapentin—epilepsy syndrome	2.7e-05	0.000172	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Pregabalin—epilepsy syndrome	2.69e-05	0.000172	CcSEcCtD
Gliclazide—Hypotension—Valproic Acid—epilepsy syndrome	2.69e-05	0.000171	CcSEcCtD
Gliclazide—Asthenia—Carbamazepine—epilepsy syndrome	2.69e-05	0.000171	CcSEcCtD
Gliclazide—Agitation—Gabapentin—epilepsy syndrome	2.68e-05	0.000171	CcSEcCtD
Gliclazide—Diarrhoea—Phenytoin—epilepsy syndrome	2.68e-05	0.000171	CcSEcCtD
Gliclazide—Discomfort—Pregabalin—epilepsy syndrome	2.68e-05	0.000171	CcSEcCtD
Gliclazide—Nausea—Fosphenytoin—epilepsy syndrome	2.68e-05	0.000171	CcSEcCtD
Gliclazide—Diarrhoea—Oxcarbazepine—epilepsy syndrome	2.67e-05	0.00017	CcSEcCtD
Gliclazide—Erythema multiforme—Topiramate—epilepsy syndrome	2.67e-05	0.00017	CcSEcCtD
Gliclazide—Angioedema—Gabapentin—epilepsy syndrome	2.67e-05	0.00017	CcSEcCtD
Gliclazide—Hypersensitivity—Lamotrigine—epilepsy syndrome	2.67e-05	0.00017	CcSEcCtD
Gliclazide—Vomiting—Felbamate—epilepsy syndrome	2.66e-05	0.00017	CcSEcCtD
Gliclazide—Dry mouth—Pregabalin—epilepsy syndrome	2.65e-05	0.000169	CcSEcCtD
Gliclazide—Pruritus—Carbamazepine—epilepsy syndrome	2.65e-05	0.000169	CcSEcCtD
Gliclazide—Rash—Felbamate—epilepsy syndrome	2.64e-05	0.000168	CcSEcCtD
Gliclazide—Eye disorder—Topiramate—epilepsy syndrome	2.64e-05	0.000168	CcSEcCtD
Gliclazide—Dermatitis—Felbamate—epilepsy syndrome	2.64e-05	0.000168	CcSEcCtD
Gliclazide—Malaise—Gabapentin—epilepsy syndrome	2.63e-05	0.000168	CcSEcCtD
Gliclazide—Tinnitus—Topiramate—epilepsy syndrome	2.63e-05	0.000168	CcSEcCtD
Gliclazide—Headache—Felbamate—epilepsy syndrome	2.62e-05	0.000167	CcSEcCtD
Gliclazide—Confusional state—Pregabalin—epilepsy syndrome	2.62e-05	0.000167	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Valproic Acid—epilepsy syndrome	2.62e-05	0.000167	CcSEcCtD
Gliclazide—Flushing—Topiramate—epilepsy syndrome	2.62e-05	0.000167	CcSEcCtD
Gliclazide—Leukopenia—Gabapentin—epilepsy syndrome	2.61e-05	0.000167	CcSEcCtD
Gliclazide—Dizziness—Clonazepam—epilepsy syndrome	2.61e-05	0.000166	CcSEcCtD
Gliclazide—Nausea—Vigabatrin—epilepsy syndrome	2.61e-05	0.000166	CcSEcCtD
Gliclazide—Vomiting—Zonisamide—epilepsy syndrome	2.6e-05	0.000166	CcSEcCtD
Gliclazide—Insomnia—Valproic Acid—epilepsy syndrome	2.6e-05	0.000166	CcSEcCtD
Gliclazide—Asthenia—Lamotrigine—epilepsy syndrome	2.6e-05	0.000165	CcSEcCtD
Gliclazide—Dizziness—Phenytoin—epilepsy syndrome	2.59e-05	0.000165	CcSEcCtD
Gliclazide—Rash—Zonisamide—epilepsy syndrome	2.58e-05	0.000165	CcSEcCtD
Gliclazide—Infection—Pregabalin—epilepsy syndrome	2.58e-05	0.000165	CcSEcCtD
Gliclazide—Paraesthesia—Valproic Acid—epilepsy syndrome	2.58e-05	0.000165	CcSEcCtD
Gliclazide—Palpitations—Gabapentin—epilepsy syndrome	2.58e-05	0.000164	CcSEcCtD
Gliclazide—Dermatitis—Zonisamide—epilepsy syndrome	2.58e-05	0.000164	CcSEcCtD
Gliclazide—Dizziness—Oxcarbazepine—epilepsy syndrome	2.58e-05	0.000164	CcSEcCtD
Gliclazide—Nausea—Diazepam—epilepsy syndrome	2.57e-05	0.000164	CcSEcCtD
Gliclazide—Loss of consciousness—Gabapentin—epilepsy syndrome	2.57e-05	0.000164	CcSEcCtD
Gliclazide—Headache—Zonisamide—epilepsy syndrome	2.57e-05	0.000164	CcSEcCtD
Gliclazide—Dyspnoea—Valproic Acid—epilepsy syndrome	2.56e-05	0.000163	CcSEcCtD
Gliclazide—Diarrhoea—Carbamazepine—epilepsy syndrome	2.56e-05	0.000163	CcSEcCtD
Gliclazide—Pruritus—Lamotrigine—epilepsy syndrome	2.56e-05	0.000163	CcSEcCtD
Gliclazide—Somnolence—Valproic Acid—epilepsy syndrome	2.56e-05	0.000163	CcSEcCtD
Gliclazide—Nervous system disorder—Pregabalin—epilepsy syndrome	2.55e-05	0.000162	CcSEcCtD
Gliclazide—Cough—Gabapentin—epilepsy syndrome	2.55e-05	0.000162	CcSEcCtD
Gliclazide—Thrombocytopenia—Pregabalin—epilepsy syndrome	2.54e-05	0.000162	CcSEcCtD
Gliclazide—Tachycardia—Pregabalin—epilepsy syndrome	2.54e-05	0.000162	CcSEcCtD
Gliclazide—Chills—Topiramate—epilepsy syndrome	2.53e-05	0.000161	CcSEcCtD
Gliclazide—Dyspepsia—Valproic Acid—epilepsy syndrome	2.53e-05	0.000161	CcSEcCtD
Gliclazide—Convulsion—Gabapentin—epilepsy syndrome	2.53e-05	0.000161	CcSEcCtD
Gliclazide—Skin disorder—Pregabalin—epilepsy syndrome	2.52e-05	0.000161	CcSEcCtD
Gliclazide—Hypertension—Gabapentin—epilepsy syndrome	2.52e-05	0.000161	CcSEcCtD
Gliclazide—Hyperhidrosis—Pregabalin—epilepsy syndrome	2.51e-05	0.00016	CcSEcCtD
Gliclazide—Vomiting—Clonazepam—epilepsy syndrome	2.51e-05	0.00016	CcSEcCtD
Gliclazide—Vomiting—Phenytoin—epilepsy syndrome	2.49e-05	0.000159	CcSEcCtD
Gliclazide—Rash—Clonazepam—epilepsy syndrome	2.49e-05	0.000159	CcSEcCtD
Gliclazide—Dermatitis—Clonazepam—epilepsy syndrome	2.49e-05	0.000159	CcSEcCtD
Gliclazide—Chest pain—Gabapentin—epilepsy syndrome	2.49e-05	0.000158	CcSEcCtD
Gliclazide—Arthralgia—Gabapentin—epilepsy syndrome	2.49e-05	0.000158	CcSEcCtD
Gliclazide—Myalgia—Gabapentin—epilepsy syndrome	2.49e-05	0.000158	CcSEcCtD
Gliclazide—Nausea—Felbamate—epilepsy syndrome	2.49e-05	0.000158	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Valproic Acid—epilepsy syndrome	2.48e-05	0.000158	CcSEcCtD
Gliclazide—Vomiting—Oxcarbazepine—epilepsy syndrome	2.48e-05	0.000158	CcSEcCtD
Gliclazide—Fatigue—Valproic Acid—epilepsy syndrome	2.48e-05	0.000158	CcSEcCtD
Gliclazide—Anxiety—Gabapentin—epilepsy syndrome	2.48e-05	0.000158	CcSEcCtD
Gliclazide—Dizziness—Carbamazepine—epilepsy syndrome	2.48e-05	0.000158	CcSEcCtD
Gliclazide—Diarrhoea—Lamotrigine—epilepsy syndrome	2.48e-05	0.000158	CcSEcCtD
Gliclazide—Headache—Clonazepam—epilepsy syndrome	2.47e-05	0.000158	CcSEcCtD
Gliclazide—Rash—Phenytoin—epilepsy syndrome	2.47e-05	0.000158	CcSEcCtD
Gliclazide—Mental disorder—Topiramate—epilepsy syndrome	2.47e-05	0.000158	CcSEcCtD
Gliclazide—Dermatitis—Phenytoin—epilepsy syndrome	2.47e-05	0.000157	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Gabapentin—epilepsy syndrome	2.47e-05	0.000157	CcSEcCtD
Gliclazide—Rash—Oxcarbazepine—epilepsy syndrome	2.46e-05	0.000157	CcSEcCtD
Gliclazide—Constipation—Valproic Acid—epilepsy syndrome	2.46e-05	0.000157	CcSEcCtD
Gliclazide—Pain—Valproic Acid—epilepsy syndrome	2.46e-05	0.000157	CcSEcCtD
Gliclazide—Dermatitis—Oxcarbazepine—epilepsy syndrome	2.46e-05	0.000157	CcSEcCtD
Gliclazide—Headache—Phenytoin—epilepsy syndrome	2.46e-05	0.000157	CcSEcCtD
Gliclazide—Malnutrition—Topiramate—epilepsy syndrome	2.46e-05	0.000157	CcSEcCtD
Gliclazide—Erythema—Topiramate—epilepsy syndrome	2.46e-05	0.000157	CcSEcCtD
Gliclazide—Discomfort—Gabapentin—epilepsy syndrome	2.46e-05	0.000157	CcSEcCtD
Gliclazide—Headache—Oxcarbazepine—epilepsy syndrome	2.44e-05	0.000156	CcSEcCtD
Gliclazide—Nausea—Zonisamide—epilepsy syndrome	2.43e-05	0.000155	CcSEcCtD
Gliclazide—Dry mouth—Gabapentin—epilepsy syndrome	2.43e-05	0.000155	CcSEcCtD
Gliclazide—Hypotension—Pregabalin—epilepsy syndrome	2.43e-05	0.000155	CcSEcCtD
Gliclazide—Flatulence—Topiramate—epilepsy syndrome	2.42e-05	0.000154	CcSEcCtD
Gliclazide—Tension—Topiramate—epilepsy syndrome	2.41e-05	0.000154	CcSEcCtD
Gliclazide—Confusional state—Gabapentin—epilepsy syndrome	2.4e-05	0.000153	CcSEcCtD
Gliclazide—Dizziness—Lamotrigine—epilepsy syndrome	2.39e-05	0.000152	CcSEcCtD
Gliclazide—Nervousness—Topiramate—epilepsy syndrome	2.39e-05	0.000152	CcSEcCtD
Gliclazide—Vomiting—Carbamazepine—epilepsy syndrome	2.38e-05	0.000152	CcSEcCtD
Gliclazide—Back pain—Topiramate—epilepsy syndrome	2.38e-05	0.000151	CcSEcCtD
Gliclazide—Feeling abnormal—Valproic Acid—epilepsy syndrome	2.37e-05	0.000151	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Pregabalin—epilepsy syndrome	2.37e-05	0.000151	CcSEcCtD
Gliclazide—Infection—Gabapentin—epilepsy syndrome	2.37e-05	0.000151	CcSEcCtD
Gliclazide—Rash—Carbamazepine—epilepsy syndrome	2.36e-05	0.00015	CcSEcCtD
Gliclazide—Dermatitis—Carbamazepine—epilepsy syndrome	2.36e-05	0.00015	CcSEcCtD
Gliclazide—Gastrointestinal pain—Valproic Acid—epilepsy syndrome	2.35e-05	0.00015	CcSEcCtD
Gliclazide—Insomnia—Pregabalin—epilepsy syndrome	2.35e-05	0.00015	CcSEcCtD
Gliclazide—Nausea—Clonazepam—epilepsy syndrome	2.34e-05	0.000149	CcSEcCtD
Gliclazide—Headache—Carbamazepine—epilepsy syndrome	2.34e-05	0.000149	CcSEcCtD
Gliclazide—Nervous system disorder—Gabapentin—epilepsy syndrome	2.34e-05	0.000149	CcSEcCtD
Gliclazide—Paraesthesia—Pregabalin—epilepsy syndrome	2.33e-05	0.000149	CcSEcCtD
Gliclazide—Thrombocytopenia—Gabapentin—epilepsy syndrome	2.33e-05	0.000149	CcSEcCtD
Gliclazide—Nausea—Phenytoin—epilepsy syndrome	2.33e-05	0.000148	CcSEcCtD
Gliclazide—Tachycardia—Gabapentin—epilepsy syndrome	2.33e-05	0.000148	CcSEcCtD
Gliclazide—Dyspnoea—Pregabalin—epilepsy syndrome	2.32e-05	0.000148	CcSEcCtD
Gliclazide—Nausea—Oxcarbazepine—epilepsy syndrome	2.32e-05	0.000148	CcSEcCtD
Gliclazide—Skin disorder—Gabapentin—epilepsy syndrome	2.31e-05	0.000148	CcSEcCtD
Gliclazide—Somnolence—Pregabalin—epilepsy syndrome	2.31e-05	0.000147	CcSEcCtD
Gliclazide—Hyperhidrosis—Gabapentin—epilepsy syndrome	2.3e-05	0.000147	CcSEcCtD
Gliclazide—Tremor—Topiramate—epilepsy syndrome	2.3e-05	0.000147	CcSEcCtD
Gliclazide—Vomiting—Lamotrigine—epilepsy syndrome	2.3e-05	0.000147	CcSEcCtD
Gliclazide—Urticaria—Valproic Acid—epilepsy syndrome	2.28e-05	0.000146	CcSEcCtD
Gliclazide—Rash—Lamotrigine—epilepsy syndrome	2.28e-05	0.000145	CcSEcCtD
Gliclazide—Ill-defined disorder—Topiramate—epilepsy syndrome	2.28e-05	0.000145	CcSEcCtD
Gliclazide—Dermatitis—Lamotrigine—epilepsy syndrome	2.28e-05	0.000145	CcSEcCtD
Gliclazide—Body temperature increased—Valproic Acid—epilepsy syndrome	2.27e-05	0.000145	CcSEcCtD
Gliclazide—Abdominal pain—Valproic Acid—epilepsy syndrome	2.27e-05	0.000145	CcSEcCtD
Gliclazide—Anaemia—Topiramate—epilepsy syndrome	2.27e-05	0.000145	CcSEcCtD
Gliclazide—Headache—Lamotrigine—epilepsy syndrome	2.27e-05	0.000144	CcSEcCtD
Gliclazide—Agitation—Topiramate—epilepsy syndrome	2.26e-05	0.000144	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Pregabalin—epilepsy syndrome	2.24e-05	0.000143	CcSEcCtD
Gliclazide—Fatigue—Pregabalin—epilepsy syndrome	2.24e-05	0.000143	CcSEcCtD
Gliclazide—Hypotension—Gabapentin—epilepsy syndrome	2.23e-05	0.000142	CcSEcCtD
Gliclazide—Nausea—Carbamazepine—epilepsy syndrome	2.22e-05	0.000142	CcSEcCtD
Gliclazide—Constipation—Pregabalin—epilepsy syndrome	2.22e-05	0.000142	CcSEcCtD
Gliclazide—Pain—Pregabalin—epilepsy syndrome	2.22e-05	0.000142	CcSEcCtD
Gliclazide—Malaise—Topiramate—epilepsy syndrome	2.22e-05	0.000141	CcSEcCtD
Gliclazide—Leukopenia—Topiramate—epilepsy syndrome	2.2e-05	0.00014	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Gabapentin—epilepsy syndrome	2.17e-05	0.000138	CcSEcCtD
Gliclazide—Palpitations—Topiramate—epilepsy syndrome	2.17e-05	0.000138	CcSEcCtD
Gliclazide—Loss of consciousness—Topiramate—epilepsy syndrome	2.16e-05	0.000138	CcSEcCtD
Gliclazide—Insomnia—Gabapentin—epilepsy syndrome	2.16e-05	0.000137	CcSEcCtD
Gliclazide—Nausea—Lamotrigine—epilepsy syndrome	2.15e-05	0.000137	CcSEcCtD
Gliclazide—Cough—Topiramate—epilepsy syndrome	2.14e-05	0.000137	CcSEcCtD
Gliclazide—Feeling abnormal—Pregabalin—epilepsy syndrome	2.14e-05	0.000137	CcSEcCtD
Gliclazide—Paraesthesia—Gabapentin—epilepsy syndrome	2.14e-05	0.000136	CcSEcCtD
Gliclazide—Convulsion—Topiramate—epilepsy syndrome	2.13e-05	0.000136	CcSEcCtD
Gliclazide—Gastrointestinal pain—Pregabalin—epilepsy syndrome	2.13e-05	0.000135	CcSEcCtD
Gliclazide—Dyspnoea—Gabapentin—epilepsy syndrome	2.12e-05	0.000135	CcSEcCtD
Gliclazide—Hypertension—Topiramate—epilepsy syndrome	2.12e-05	0.000135	CcSEcCtD
Gliclazide—Somnolence—Gabapentin—epilepsy syndrome	2.12e-05	0.000135	CcSEcCtD
Gliclazide—Hypersensitivity—Valproic Acid—epilepsy syndrome	2.12e-05	0.000135	CcSEcCtD
Gliclazide—Dyspepsia—Gabapentin—epilepsy syndrome	2.1e-05	0.000134	CcSEcCtD
Gliclazide—Myalgia—Topiramate—epilepsy syndrome	2.09e-05	0.000133	CcSEcCtD
Gliclazide—Chest pain—Topiramate—epilepsy syndrome	2.09e-05	0.000133	CcSEcCtD
Gliclazide—Arthralgia—Topiramate—epilepsy syndrome	2.09e-05	0.000133	CcSEcCtD
Gliclazide—Anxiety—Topiramate—epilepsy syndrome	2.08e-05	0.000133	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Topiramate—epilepsy syndrome	2.08e-05	0.000132	CcSEcCtD
Gliclazide—Discomfort—Topiramate—epilepsy syndrome	2.07e-05	0.000132	CcSEcCtD
Gliclazide—Urticaria—Pregabalin—epilepsy syndrome	2.06e-05	0.000132	CcSEcCtD
Gliclazide—Asthenia—Valproic Acid—epilepsy syndrome	2.06e-05	0.000131	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Gabapentin—epilepsy syndrome	2.06e-05	0.000131	CcSEcCtD
Gliclazide—Fatigue—Gabapentin—epilepsy syndrome	2.05e-05	0.000131	CcSEcCtD
Gliclazide—Abdominal pain—Pregabalin—epilepsy syndrome	2.05e-05	0.000131	CcSEcCtD
Gliclazide—Body temperature increased—Pregabalin—epilepsy syndrome	2.05e-05	0.000131	CcSEcCtD
Gliclazide—Dry mouth—Topiramate—epilepsy syndrome	2.05e-05	0.00013	CcSEcCtD
Gliclazide—Pain—Gabapentin—epilepsy syndrome	2.04e-05	0.00013	CcSEcCtD
Gliclazide—Constipation—Gabapentin—epilepsy syndrome	2.04e-05	0.00013	CcSEcCtD
Gliclazide—Pruritus—Valproic Acid—epilepsy syndrome	2.03e-05	0.00013	CcSEcCtD
Gliclazide—Confusional state—Topiramate—epilepsy syndrome	2.02e-05	0.000129	CcSEcCtD
Gliclazide—Infection—Topiramate—epilepsy syndrome	1.99e-05	0.000127	CcSEcCtD
Gliclazide—Diarrhoea—Valproic Acid—epilepsy syndrome	1.97e-05	0.000125	CcSEcCtD
Gliclazide—Nervous system disorder—Topiramate—epilepsy syndrome	1.97e-05	0.000125	CcSEcCtD
Gliclazide—Feeling abnormal—Gabapentin—epilepsy syndrome	1.96e-05	0.000125	CcSEcCtD
Gliclazide—Thrombocytopenia—Topiramate—epilepsy syndrome	1.96e-05	0.000125	CcSEcCtD
Gliclazide—Tachycardia—Topiramate—epilepsy syndrome	1.96e-05	0.000125	CcSEcCtD
Gliclazide—Gastrointestinal pain—Gabapentin—epilepsy syndrome	1.95e-05	0.000124	CcSEcCtD
Gliclazide—Skin disorder—Topiramate—epilepsy syndrome	1.95e-05	0.000124	CcSEcCtD
Gliclazide—Hyperhidrosis—Topiramate—epilepsy syndrome	1.94e-05	0.000124	CcSEcCtD
Gliclazide—Hypersensitivity—Pregabalin—epilepsy syndrome	1.91e-05	0.000122	CcSEcCtD
Gliclazide—Dizziness—Valproic Acid—epilepsy syndrome	1.9e-05	0.000121	CcSEcCtD
Gliclazide—Urticaria—Gabapentin—epilepsy syndrome	1.89e-05	0.000121	CcSEcCtD
Gliclazide—Body temperature increased—Gabapentin—epilepsy syndrome	1.88e-05	0.00012	CcSEcCtD
Gliclazide—Abdominal pain—Gabapentin—epilepsy syndrome	1.88e-05	0.00012	CcSEcCtD
Gliclazide—Hypotension—Topiramate—epilepsy syndrome	1.87e-05	0.000119	CcSEcCtD
Gliclazide—Asthenia—Pregabalin—epilepsy syndrome	1.86e-05	0.000119	CcSEcCtD
Gliclazide—Pruritus—Pregabalin—epilepsy syndrome	1.84e-05	0.000117	CcSEcCtD
Gliclazide—Vomiting—Valproic Acid—epilepsy syndrome	1.83e-05	0.000117	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Topiramate—epilepsy syndrome	1.83e-05	0.000116	CcSEcCtD
Gliclazide—Insomnia—Topiramate—epilepsy syndrome	1.81e-05	0.000116	CcSEcCtD
Gliclazide—Rash—Valproic Acid—epilepsy syndrome	1.81e-05	0.000116	CcSEcCtD
Gliclazide—Dermatitis—Valproic Acid—epilepsy syndrome	1.81e-05	0.000115	CcSEcCtD
Gliclazide—Headache—Valproic Acid—epilepsy syndrome	1.8e-05	0.000115	CcSEcCtD
Gliclazide—Paraesthesia—Topiramate—epilepsy syndrome	1.8e-05	0.000115	CcSEcCtD
Gliclazide—Dyspnoea—Topiramate—epilepsy syndrome	1.79e-05	0.000114	CcSEcCtD
Gliclazide—Somnolence—Topiramate—epilepsy syndrome	1.78e-05	0.000114	CcSEcCtD
Gliclazide—Diarrhoea—Pregabalin—epilepsy syndrome	1.78e-05	0.000113	CcSEcCtD
Gliclazide—Dyspepsia—Topiramate—epilepsy syndrome	1.76e-05	0.000113	CcSEcCtD
Gliclazide—Hypersensitivity—Gabapentin—epilepsy syndrome	1.76e-05	0.000112	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Topiramate—epilepsy syndrome	1.73e-05	0.00011	CcSEcCtD
Gliclazide—Fatigue—Topiramate—epilepsy syndrome	1.73e-05	0.00011	CcSEcCtD
Gliclazide—Dizziness—Pregabalin—epilepsy syndrome	1.72e-05	0.00011	CcSEcCtD
Gliclazide—Pain—Topiramate—epilepsy syndrome	1.71e-05	0.000109	CcSEcCtD
Gliclazide—Constipation—Topiramate—epilepsy syndrome	1.71e-05	0.000109	CcSEcCtD
Gliclazide—Asthenia—Gabapentin—epilepsy syndrome	1.71e-05	0.000109	CcSEcCtD
Gliclazide—Nausea—Valproic Acid—epilepsy syndrome	1.71e-05	0.000109	CcSEcCtD
Gliclazide—Pruritus—Gabapentin—epilepsy syndrome	1.69e-05	0.000107	CcSEcCtD
Gliclazide—Vomiting—Pregabalin—epilepsy syndrome	1.65e-05	0.000105	CcSEcCtD
Gliclazide—Feeling abnormal—Topiramate—epilepsy syndrome	1.65e-05	0.000105	CcSEcCtD
Gliclazide—Gastrointestinal pain—Topiramate—epilepsy syndrome	1.64e-05	0.000105	CcSEcCtD
Gliclazide—Rash—Pregabalin—epilepsy syndrome	1.64e-05	0.000104	CcSEcCtD
Gliclazide—Dermatitis—Pregabalin—epilepsy syndrome	1.64e-05	0.000104	CcSEcCtD
Gliclazide—Diarrhoea—Gabapentin—epilepsy syndrome	1.63e-05	0.000104	CcSEcCtD
Gliclazide—Headache—Pregabalin—epilepsy syndrome	1.63e-05	0.000104	CcSEcCtD
Gliclazide—Urticaria—Topiramate—epilepsy syndrome	1.59e-05	0.000102	CcSEcCtD
Gliclazide—Abdominal pain—Topiramate—epilepsy syndrome	1.58e-05	0.000101	CcSEcCtD
Gliclazide—Body temperature increased—Topiramate—epilepsy syndrome	1.58e-05	0.000101	CcSEcCtD
Gliclazide—Dizziness—Gabapentin—epilepsy syndrome	1.58e-05	0.0001	CcSEcCtD
Gliclazide—Nausea—Pregabalin—epilepsy syndrome	1.54e-05	9.84e-05	CcSEcCtD
Gliclazide—Vomiting—Gabapentin—epilepsy syndrome	1.52e-05	9.66e-05	CcSEcCtD
Gliclazide—Rash—Gabapentin—epilepsy syndrome	1.5e-05	9.58e-05	CcSEcCtD
Gliclazide—Dermatitis—Gabapentin—epilepsy syndrome	1.5e-05	9.57e-05	CcSEcCtD
Gliclazide—Headache—Gabapentin—epilepsy syndrome	1.49e-05	9.52e-05	CcSEcCtD
Gliclazide—Hypersensitivity—Topiramate—epilepsy syndrome	1.48e-05	9.42e-05	CcSEcCtD
Gliclazide—Asthenia—Topiramate—epilepsy syndrome	1.44e-05	9.17e-05	CcSEcCtD
Gliclazide—Pruritus—Topiramate—epilepsy syndrome	1.42e-05	9.04e-05	CcSEcCtD
Gliclazide—Nausea—Gabapentin—epilepsy syndrome	1.42e-05	9.02e-05	CcSEcCtD
Gliclazide—Diarrhoea—Topiramate—epilepsy syndrome	1.37e-05	8.74e-05	CcSEcCtD
Gliclazide—Dizziness—Topiramate—epilepsy syndrome	1.33e-05	8.45e-05	CcSEcCtD
Gliclazide—Vomiting—Topiramate—epilepsy syndrome	1.27e-05	8.13e-05	CcSEcCtD
Gliclazide—Rash—Topiramate—epilepsy syndrome	1.26e-05	8.06e-05	CcSEcCtD
Gliclazide—Dermatitis—Topiramate—epilepsy syndrome	1.26e-05	8.05e-05	CcSEcCtD
Gliclazide—Headache—Topiramate—epilepsy syndrome	1.26e-05	8.01e-05	CcSEcCtD
Gliclazide—Nausea—Topiramate—epilepsy syndrome	1.19e-05	7.59e-05	CcSEcCtD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—CYP2C19—epilepsy syndrome	8.83e-06	0.000109	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—CYP11A1—epilepsy syndrome	8.77e-06	0.000108	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—ABCG2—epilepsy syndrome	8.62e-06	0.000106	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—MMP9—epilepsy syndrome	8.61e-06	0.000106	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—COX3—epilepsy syndrome	8.55e-06	0.000105	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—ATP2A2—epilepsy syndrome	8.4e-06	0.000103	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TSC1—epilepsy syndrome	8.36e-06	0.000103	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PTK2B—epilepsy syndrome	8.36e-06	0.000103	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CA4—epilepsy syndrome	8.3e-06	0.000102	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—QDPR—epilepsy syndrome	8.3e-06	0.000102	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—ADRA2A—epilepsy syndrome	8.28e-06	0.000102	CbGpPWpGaD
Gliclazide—CYP2C9—Biological oxidations—POMC—epilepsy syndrome	8.27e-06	0.000102	CbGpPWpGaD
Gliclazide—ALB—Metabolism—UPB1—epilepsy syndrome	8.26e-06	0.000102	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ATIC—epilepsy syndrome	8.26e-06	0.000102	CbGpPWpGaD
Gliclazide—ALB—Metabolism—NEU1—epilepsy syndrome	8.26e-06	0.000102	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PLAT—epilepsy syndrome	8.25e-06	0.000102	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—HMOX1—epilepsy syndrome	8.14e-06	0.0001	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CCR2—epilepsy syndrome	8.13e-06	0.0001	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—SST—epilepsy syndrome	8.13e-06	0.0001	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—NTRK2—epilepsy syndrome	8.13e-06	0.0001	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CACNA2D2—epilepsy syndrome	8.11e-06	9.99e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PFKL—epilepsy syndrome	8.11e-06	9.99e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—KCNB1—epilepsy syndrome	8.11e-06	9.99e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—SLCO1A2—epilepsy syndrome	8.11e-06	9.99e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—SLC6A8—epilepsy syndrome	8.11e-06	9.99e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—DUSP6—epilepsy syndrome	8.06e-06	9.93e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—CAT—epilepsy syndrome	8.03e-06	9.89e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—ADRA2A—epilepsy syndrome	7.96e-06	9.8e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—HSD17B4—epilepsy syndrome	7.95e-06	9.8e-05	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—SRC—epilepsy syndrome	7.94e-06	9.78e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PLAT—epilepsy syndrome	7.92e-06	9.76e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—HMOX1—epilepsy syndrome	7.89e-06	9.72e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—CYP11A1—epilepsy syndrome	7.88e-06	9.7e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—ABCB1—epilepsy syndrome	7.81e-06	9.62e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—COX3—epilepsy syndrome	7.8e-06	9.61e-05	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—SRC—epilepsy syndrome	7.79e-06	9.6e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—CAT—epilepsy syndrome	7.79e-06	9.59e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—NOS1—epilepsy syndrome	7.75e-06	9.55e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GBE1—epilepsy syndrome	7.68e-06	9.46e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PPP1R3C—epilepsy syndrome	7.68e-06	9.46e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—BDKRB2—epilepsy syndrome	7.64e-06	9.42e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CXCL12—epilepsy syndrome	7.64e-06	9.42e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—ABCB1—epilepsy syndrome	7.57e-06	9.33e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—BCHE—epilepsy syndrome	7.51e-06	9.25e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—JUNB—epilepsy syndrome	7.5e-06	9.24e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CNR1—epilepsy syndrome	7.5e-06	9.24e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PLCB1—epilepsy syndrome	7.48e-06	9.21e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—UPB1—epilepsy syndrome	7.42e-06	9.14e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—NEU1—epilepsy syndrome	7.42e-06	9.14e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ATIC—epilepsy syndrome	7.42e-06	9.14e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—KCNB1—epilepsy syndrome	7.39e-06	9.11e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PFKL—epilepsy syndrome	7.39e-06	9.11e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CACNA2D2—epilepsy syndrome	7.39e-06	9.11e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—SLCO1A2—epilepsy syndrome	7.39e-06	9.11e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—SLC6A8—epilepsy syndrome	7.39e-06	9.11e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—HTR7—epilepsy syndrome	7.32e-06	9.02e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—GPX1—epilepsy syndrome	7.26e-06	8.95e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—AKT3—epilepsy syndrome	7.26e-06	8.94e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—CYP2C19—epilepsy syndrome	7.23e-06	8.9e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ASAH1—epilepsy syndrome	7.22e-06	8.9e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—CYP11A1—epilepsy syndrome	7.18e-06	8.85e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PLAUR—epilepsy syndrome	7.17e-06	8.84e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—HSD17B4—epilepsy syndrome	7.14e-06	8.8e-05	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—PLAT—epilepsy syndrome	7.14e-06	8.79e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—HBEGF—epilepsy syndrome	7.11e-06	8.75e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—GPX1—epilepsy syndrome	7.04e-06	8.67e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—STXBP1—epilepsy syndrome	7.03e-06	8.66e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—AKT3—epilepsy syndrome	6.97e-06	8.59e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PPP1R3C—epilepsy syndrome	6.9e-06	8.49e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GBE1—epilepsy syndrome	6.9e-06	8.49e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—NT5E—epilepsy syndrome	6.85e-06	8.43e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ALAD—epilepsy syndrome	6.85e-06	8.43e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—ADAM10—epilepsy syndrome	6.81e-06	8.39e-05	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—SLC2A1—epilepsy syndrome	6.81e-06	8.39e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—UPB1—epilepsy syndrome	6.76e-06	8.33e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ATIC—epilepsy syndrome	6.76e-06	8.33e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—NEU1—epilepsy syndrome	6.76e-06	8.33e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—epilepsy syndrome	6.74e-06	8.3e-05	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—TNF—epilepsy syndrome	6.63e-06	8.17e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—CDC42—epilepsy syndrome	6.62e-06	8.16e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CACNA1A—epilepsy syndrome	6.53e-06	8.05e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ALDH7A1—epilepsy syndrome	6.53e-06	8.05e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—HSD17B4—epilepsy syndrome	6.51e-06	8.02e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ASAH1—epilepsy syndrome	6.48e-06	7.99e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—S100B—epilepsy syndrome	6.44e-06	7.94e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ST3GAL3—epilepsy syndrome	6.39e-06	7.87e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—SOCS3—epilepsy syndrome	6.38e-06	7.86e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—AGT—epilepsy syndrome	6.37e-06	7.84e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CDC42—epilepsy syndrome	6.36e-06	7.84e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—STXBP1—epilepsy syndrome	6.31e-06	7.77e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GBE1—epilepsy syndrome	6.29e-06	7.75e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PPP1R3C—epilepsy syndrome	6.29e-06	7.75e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ADSL—epilepsy syndrome	6.26e-06	7.71e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—APOE—epilepsy syndrome	6.24e-06	7.69e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—AGT—epilepsy syndrome	6.17e-06	7.61e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—AVP—epilepsy syndrome	6.16e-06	7.59e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—NT5E—epilepsy syndrome	6.15e-06	7.57e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ALAD—epilepsy syndrome	6.15e-06	7.57e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—epilepsy syndrome	6.15e-06	7.57e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GLUL—epilepsy syndrome	6.14e-06	7.57e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—APOE—epilepsy syndrome	6.05e-06	7.45e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CACNA1D—epilepsy syndrome	6.03e-06	7.43e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ASAH1—epilepsy syndrome	5.91e-06	7.28e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—FYN—epilepsy syndrome	5.9e-06	7.26e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ALDH7A1—epilepsy syndrome	5.86e-06	7.22e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CACNA1A—epilepsy syndrome	5.86e-06	7.22e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—HES1—epilepsy syndrome	5.83e-06	7.18e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—STXBP1—epilepsy syndrome	5.75e-06	7.08e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ST3GAL3—epilepsy syndrome	5.74e-06	7.07e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—YWHAZ—epilepsy syndrome	5.67e-06	6.98e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—FYN—epilepsy syndrome	5.67e-06	6.98e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—H2AFX—epilepsy syndrome	5.64e-06	6.95e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—TXNRD1—epilepsy syndrome	5.64e-06	6.95e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MEF2C—epilepsy syndrome	5.63e-06	6.94e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ADSL—epilepsy syndrome	5.62e-06	6.93e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—NT5E—epilepsy syndrome	5.6e-06	6.9e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ALAD—epilepsy syndrome	5.6e-06	6.9e-05	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—HMOX1—epilepsy syndrome	5.6e-06	6.9e-05	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—AVP—epilepsy syndrome	5.55e-06	6.84e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GLUL—epilepsy syndrome	5.51e-06	6.79e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—AQP1—epilepsy syndrome	5.47e-06	6.74e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—YWHAZ—epilepsy syndrome	5.45e-06	6.71e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CACNA1D—epilepsy syndrome	5.41e-06	6.67e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—NGF—epilepsy syndrome	5.38e-06	6.63e-05	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—ABCB1—epilepsy syndrome	5.38e-06	6.62e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—POMC—epilepsy syndrome	5.36e-06	6.6e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ALDH7A1—epilepsy syndrome	5.35e-06	6.59e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CACNA1A—epilepsy syndrome	5.35e-06	6.59e-05	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—SRC—epilepsy syndrome	5.33e-06	6.57e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—GPX1—epilepsy syndrome	5.26e-06	6.48e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CCR5—epilepsy syndrome	5.24e-06	6.45e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ST3GAL3—epilepsy syndrome	5.23e-06	6.45e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—POMC—epilepsy syndrome	5.2e-06	6.4e-05	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—VEGFA—epilepsy syndrome	5.19e-06	6.4e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—HTR2A—epilepsy syndrome	5.13e-06	6.32e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ADSL—epilepsy syndrome	5.13e-06	6.31e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—TXNRD1—epilepsy syndrome	5.06e-06	6.24e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PLAU—epilepsy syndrome	5.03e-06	6.2e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GLUL—epilepsy syndrome	5.03e-06	6.19e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CHRM3—epilepsy syndrome	4.95e-06	6.1e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—KCNJ11—epilepsy syndrome	4.95e-06	6.1e-05	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—AKT1—epilepsy syndrome	4.93e-06	6.08e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CACNA1D—epilepsy syndrome	4.93e-06	6.08e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—AQP1—epilepsy syndrome	4.91e-06	6.05e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—ALB—epilepsy syndrome	4.89e-06	6.02e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TSC2—epilepsy syndrome	4.87e-06	6e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—AGT—epilepsy syndrome	4.86e-06	5.99e-05	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—AKT1—epilepsy syndrome	4.84e-06	5.96e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—APOE—epilepsy syndrome	4.77e-06	5.87e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—ALB—epilepsy syndrome	4.74e-06	5.84e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—epilepsy syndrome	4.72e-06	5.81e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PRKCB—epilepsy syndrome	4.68e-06	5.76e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—KDR—epilepsy syndrome	4.67e-06	5.75e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—NOS2—epilepsy syndrome	4.62e-06	5.7e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—TXNRD1—epilepsy syndrome	4.61e-06	5.69e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—AGT—epilepsy syndrome	4.61e-06	5.68e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—APOE—epilepsy syndrome	4.52e-06	5.56e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PRKCB—epilepsy syndrome	4.49e-06	5.54e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—AQP1—epilepsy syndrome	4.48e-06	5.52e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IL6ST—epilepsy syndrome	4.48e-06	5.51e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CHRM3—epilepsy syndrome	4.44e-06	5.47e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—KCNJ11—epilepsy syndrome	4.44e-06	5.47e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—epilepsy syndrome	4.3e-06	5.3e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PTGS2—epilepsy syndrome	4.27e-06	5.27e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PTGS2—epilepsy syndrome	4.14e-06	5.11e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—AGT—epilepsy syndrome	4.14e-06	5.1e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—POMC—epilepsy syndrome	4.09e-06	5.04e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—APOE—epilepsy syndrome	4.05e-06	4.99e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CHRM3—epilepsy syndrome	4.05e-06	4.99e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—KCNJ11—epilepsy syndrome	4.05e-06	4.99e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ABCG2—epilepsy syndrome	4.04e-06	4.97e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CCL2—epilepsy syndrome	4.01e-06	4.93e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CYP2C19—epilepsy syndrome	3.93e-06	4.84e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CYP11A1—epilepsy syndrome	3.91e-06	4.81e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—POMC—epilepsy syndrome	3.88e-06	4.78e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—AGT—epilepsy syndrome	3.77e-06	4.65e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—APOE—epilepsy syndrome	3.7e-06	4.55e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ABCG2—epilepsy syndrome	3.62e-06	4.46e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—FGF2—epilepsy syndrome	3.62e-06	4.46e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CYP2D6—epilepsy syndrome	3.53e-06	4.35e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CYP11A1—epilepsy syndrome	3.51e-06	4.32e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—POMC—epilepsy syndrome	3.48e-06	4.29e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—RELA—epilepsy syndrome	3.36e-06	4.14e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ADRA2A—epilepsy syndrome	3.36e-06	4.14e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—BCHE—epilepsy syndrome	3.34e-06	4.12e-05	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—AKT1—epilepsy syndrome	3.31e-06	4.08e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ABCG2—epilepsy syndrome	3.3e-06	4.07e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MTOR—epilepsy syndrome	3.3e-06	4.06e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CYP2C19—epilepsy syndrome	3.22e-06	3.97e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CYP11A1—epilepsy syndrome	3.2e-06	3.94e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—SLC2A1—epilepsy syndrome	3.19e-06	3.93e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—POMC—epilepsy syndrome	3.18e-06	3.91e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—epilepsy syndrome	3.18e-06	3.91e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CYP2D6—epilepsy syndrome	3.17e-06	3.9e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PLCB1—epilepsy syndrome	3.15e-06	3.89e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—TH—epilepsy syndrome	3.14e-06	3.87e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	3.09e-06	3.81e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CASP3—epilepsy syndrome	3.03e-06	3.73e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ADRA2A—epilepsy syndrome	3.01e-06	3.71e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—BCHE—epilepsy syndrome	3e-06	3.7e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—JUN—epilepsy syndrome	2.94e-06	3.63e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—epilepsy syndrome	2.9e-06	3.57e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CYP2D6—epilepsy syndrome	2.89e-06	3.56e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MMP9—epilepsy syndrome	2.86e-06	3.53e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—SLC2A1—epilepsy syndrome	2.86e-06	3.53e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PLCB1—epilepsy syndrome	2.83e-06	3.49e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—TH—epilepsy syndrome	2.82e-06	3.48e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	2.78e-06	3.42e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—SRC—epilepsy syndrome	2.75e-06	3.39e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ADRA2A—epilepsy syndrome	2.75e-06	3.39e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—BCHE—epilepsy syndrome	2.74e-06	3.37e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—VEGFA—epilepsy syndrome	2.68e-06	3.3e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—SRC—epilepsy syndrome	2.64e-06	3.25e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—HMOX1—epilepsy syndrome	2.62e-06	3.23e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—SLC2A1—epilepsy syndrome	2.61e-06	3.22e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CAT—epilepsy syndrome	2.59e-06	3.19e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PLCB1—epilepsy syndrome	2.58e-06	3.18e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—TH—epilepsy syndrome	2.57e-06	3.17e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	2.53e-06	3.12e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ABCB1—epilepsy syndrome	2.52e-06	3.1e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—HMOX1—epilepsy syndrome	2.36e-06	2.9e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GPX1—epilepsy syndrome	2.34e-06	2.88e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CAT—epilepsy syndrome	2.32e-06	2.86e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ABCB1—epilepsy syndrome	2.26e-06	2.78e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—AKT1—epilepsy syndrome	2.15e-06	2.65e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—HMOX1—epilepsy syndrome	2.15e-06	2.65e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CAT—epilepsy syndrome	2.12e-06	2.61e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GPX1—epilepsy syndrome	2.1e-06	2.59e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—AKT1—epilepsy syndrome	2.08e-06	2.57e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ABCB1—epilepsy syndrome	2.06e-06	2.54e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—AGT—epilepsy syndrome	2.05e-06	2.53e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—APOE—epilepsy syndrome	2.01e-06	2.48e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GPX1—epilepsy syndrome	1.92e-06	2.36e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—AGT—epilepsy syndrome	1.84e-06	2.27e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—APOE—epilepsy syndrome	1.81e-06	2.22e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—POMC—epilepsy syndrome	1.73e-06	2.13e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—AKT1—epilepsy syndrome	1.71e-06	2.1e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—AGT—epilepsy syndrome	1.68e-06	2.07e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—APOE—epilepsy syndrome	1.65e-06	2.03e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—AKT1—epilepsy syndrome	1.64e-06	2.02e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—POMC—epilepsy syndrome	1.55e-06	1.91e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—POMC—epilepsy syndrome	1.41e-06	1.74e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ALB—epilepsy syndrome	1.41e-06	1.74e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PTGS2—epilepsy syndrome	1.38e-06	1.7e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ALB—epilepsy syndrome	1.29e-06	1.59e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PTGS2—epilepsy syndrome	1.24e-06	1.52e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PTGS2—epilepsy syndrome	1.13e-06	1.39e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—AKT1—epilepsy syndrome	6.93e-07	8.53e-06	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—AKT1—epilepsy syndrome	6.22e-07	7.66e-06	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—AKT1—epilepsy syndrome	5.67e-07	6.98e-06	CbGpPWpGaD
